These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 31834353)

  • 1. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
    Gourmaud S; Shou H; Irwin DJ; Sansalone K; Jacobs LM; Lucas TH; Marsh ED; Davis KA; Jensen FE; Talos DM
    Brain; 2020 Jan; 143(1):191-209. PubMed ID: 31834353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections.
    Tai XY; Koepp M; Duncan JS; Fox N; Thompson P; Baxendale S; Liu JY; Reeves C; Michalak Z; Thom M
    Brain; 2016 Sep; 139(Pt 9):2441-55. PubMed ID: 27497924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3×Tg-AD mice.
    Yan XX; Cai Y; Shelton J; Deng SH; Luo XG; Oddo S; Laferla FM; Cai H; Rose GM; Patrylo PR
    PLoS One; 2012; 7(11):e48782. PubMed ID: 23155407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low prevalence of amyloid and tau pathology in drug-resistant temporal lobe epilepsy.
    Silva JC; Vivash L; Malpas CB; Hao Y; McLean C; Chen Z; O'Brien TJ; Jones NC; Kwan P
    Epilepsia; 2021 Dec; 62(12):3058-3067. PubMed ID: 34595752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
    Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.
    Wisse LEM; Ravikumar S; Ittyerah R; Lim S; Lane J; Bedard ML; Xie L; Das SR; Schuck T; Grossman M; Lee EB; Tisdall MD; Prabhakaran K; Detre JA; Mizsei G; Trojanowski JQ; Artacho-Pérula E; de Iñiguez de Onzono Martin MM; M Arroyo-Jiménez M; Muñoz Lopez M; Molina Romero FJ; P Marcos Rabal M; Cebada Sánchez S; Delgado González JC; de la Rosa Prieto C; Córcoles Parada M; Wolk DA; Irwin DJ; Insausti R; Yushkevich PA
    Acta Neuropathol Commun; 2021 Jul; 9(1):128. PubMed ID: 34289895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
    Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
    J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
    Li HQ; Ip SP; Yuan QJ; Zheng GQ; Tsim KKW; Dong TTX; Lin G; Han Y; Liu Y; Xian YF; Lin ZX
    Brain Behav Immun; 2019 Nov; 82():264-278. PubMed ID: 31476414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
    Li J; Deng J; Sheng W; Zuo Z
    Pharmacol Biochem Behav; 2012 Jun; 101(4):564-74. PubMed ID: 22425595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.
    Ferrer I
    Neurotox Res; 2004; 6(6):469-75. PubMed ID: 15658002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT
    Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Study of Amyloid-β and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimer's Disease Patients.
    Furcila D; DeFelipe J; Alonso-Nanclares L
    J Alzheimers Dis; 2018; 64(2):417-435. PubMed ID: 29914033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease.
    Audrain M; Souchet B; Alves S; Fol R; Viode A; Haddjeri A; Tada S; Orefice NS; Joséphine C; Bemelmans AP; Delzescaux T; Déglon N; Hantraye P; Akwa Y; Becher F; Billard JM; Potier B; Dutar P; Cartier N; Braudeau J
    Cereb Cortex; 2018 Nov; 28(11):3976-3993. PubMed ID: 29048465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease.
    Mandler M; Walker L; Santic R; Hanson P; Upadhaya AR; Colloby SJ; Morris CM; Thal DR; Thomas AJ; Schneeberger A; Attems J
    Acta Neuropathol; 2014 Jul; 128(1):67-79. PubMed ID: 24861310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages.
    Serrano FG; Tapia-Rojas C; Carvajal FJ; Cisternas P; Viayna E; Sola I; Munoz-Torrero D; Inestrosa NC
    Curr Alzheimer Res; 2016; 13(9):1017-29. PubMed ID: 26502813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.